Technology News and Research

RSS

Tiny light source and sensors in endoscope may detect esophageal cancer more accurately

A tiny light source and sensors at the end of an endoscope may provide a more accurate way to identify pre-cancerous cells in the lining of the esophagus.

4 Jan 2011

Bioniche Life Sciences announces completion of Australian Offer and raises gross proceeds of A$12.5 million

Bioniche Life Sciences In., a research-based, technology-driven Canadian biopharmaceutical company, today announced that it has successfully completed its Australian Offer of 8.6 million CHESS Depositary Instruments at A$1.45 per CDI, raising gross proceeds of A$12.5 million.

4 Jan 2011

Single cancer cell could be detected in future using new test

Soon scientists will be able to detect a single cancer cell among the billions of cells that circulate in the human bloodstream. The method could detect whether the therapy has worked or even show which therapy would work best. The test depends on circulating tumor cells (CTCs) or cancer cells that have detached from the main tumor and are traveling to other parts of the body.

4 Jan 2011

Star Scientific develops moist snuff tobacco product with low carcinogenic levels

Star Scientific, Inc. reports that it has successfully developed a moist snuff tobacco product that has extremely low levels of carcinogens -- much lower than any snuff products currently in the marketplace. This new product has levels of tobacco-specific nitrosamines (TSNAs) -- recognized by scientists worldwide as one of the most powerful cancer-causing agents in tobacco leaf and smoke -- below 20 parts per billion (nanograms-per-gram moist weight, as used) in initial testing.

4 Jan 2011

Revolutions Medical reworks exclusive license with Traxyz for breast biopsy localization system

Revolutions Medical Corporation recently completed the reworking of a worldwide exclusive license with Traxyz, LLC for an image guided navigation system to convert over 50,000 conventional mammography systems for use as a high accuracy breast biopsies system (BBS). This BBS facilitates accurate and fast non-palpable lesions and micro calcification localization in the treatment of breast cancer.

4 Jan 2011

Isis commences ISIS-EIF4ERx Phase 2 studies in non-small cell lung cancer and prostate cancer

Isis Pharmaceuticals, Inc. announced the initiation of two Phase 2 studies of ISIS-EIF4ERx in patients with non-small cell lung cancer and prostate cancer. These studies are part of Isis' broad Phase 2 development program designed to evaluate ISIS-EIF4ERx in multiple types of cancer. ISIS-EIF4ERx targets eukaryotic initiation factor-4E (eIF-4E), a traditionally "undruggable" target that is thought to promote tumor growth and metastasis in many cancers.

4 Jan 2011

STAAR Surgical exceeds 200,000 Visian ICL global implants

STAAR Surgical Company, a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today announced that the worldwide total number of Visian® ICL implants in patients has exceeded 200,000. Since 1994, STAAR's Implantable Collamer® Lenses (ICLs) have been used in refractive eye surgery as an alternative to LASIK. Manufactured with STAAR's proprietary Collamer material, Visian ICLs provide a safe and effective alternative in the permanent correction of myopia, hyperopia, and in the case of the Toric ICL, astigmatism.

4 Jan 2011

Caution over frequent use of diagnostic tests for kids

The rapid growth in use of medical diagnostic imaging, such as CT scans, has led to widespread concern about radiation exposure in adults and the potential for future cancer risk in patients undergoing these tests.

4 Jan 2011

New options in fertility preservation for oncology patients

Many young people who've just learned that they have cancer also are told that the therapies that may save their lives could rob them of their ability ever to have children. Infertility caused by chemotherapy and radiation affects a sizable population: Of the 1.5 million people diagnosed with cancer in 2009, nearly 10 percent were still in their reproductive years.

4 Jan 2011

ImmuVen to develop T cell receptor proteins for treating MRSA, cancer

Start-up company ImmuVen and the University of Illinois Urbana-Champaign have entered into a license agreement under which ImmuVen will develop modified T cell receptor proteins for the purpose of treating cancer and methicillin-resistant Staphylococcus aureus.

4 Jan 2011

FDA clears first automated molecular tests to diagnose and differentiate HSV infection

BD Diagnostics, a segment of BD, announced today that it filed for U.S. Food and Drug Administration 510(k) clearance for the first fully automated molecular tests to diagnose and differentiate HSV types 1 and 2.

From BD (Becton, Dickinson and Company) 4 Jan 2011

MGH, Veridex establish research center of excellence on circulating tumor cell technologies

Massachusetts General Hospital (MGH) has entered into a collaborative agreement with Veridex LLC to establish a center of excellence in research on circulating tumor cell (CTC) technologies. The overall goal of the agreement is to develop and commercialize novel technologies for capturing and characterizing CTCs, solid tumor cells found at extremely low levels in the bloodstream, which may offer a key to noninvasive characterization of cancer and potentially to early detection.

4 Jan 2011

New technology can help implement safe driving strategies in electric wheelchairs

Thick gravel, mud, snow, steep ramps or hills . . . They might get a pedestrian a little dirty or out of breath, but to someone in an electric wheelchair, they could mean terrain that's simply too difficult to cross alone. To address this problem, researchers at the Florida A&M University-Florida State University College of Engineering are working on technology that will enable electric-powered wheelchairs to detect hazardous terrain and automatically adjust their control settings to maneuver more safely.

4 Jan 2011

Embryome Sciences announces $4M equity financing, changes name to ReCyte Therapeutics

BioTime, Inc. today announced a $4 million equity financing by its subsidiary, Embryome Sciences, Inc. Concurrent with the financing, Embryome Sciences will be renamed ReCyte Therapeutics, Inc. and will develop therapeutic products for cardiovascular and blood diseases. The new equity financing is being led by a $2.5 million investment by private investors and a $1.5 million investment from BioTime that valued ReCyte Therapeutics at a post money valuation of $60 million on a fully diluted basis.

4 Jan 2011

Mercator, Pepscan enter multi-program cancer research collaboration

Mercator Therapeutics, the first biopharmaceutical company to systematically use in vivo phage display technology to develop novel cancer drugs and Pepscan Therapeutics, a world leader in protein mimicry technologies for improved therapeutic peptides and anti-GPCR antibodies, today announced a multi-program research collaboration. The companies will collaborate to optimize Mercator's 'Homing Peptides' using Pepscan's proprietary CLIPS technology.

4 Jan 2011

U-M research shows children are more frequently exposed to radiation through imaging tests

Children frequently exposed to medical imaging procedures that utilize radiation, U-M research shows. "Our findings indicate that more awareness about the frequent use of these tests may be needed among care providers, hospitals and parents," says Adam L. Dorfman, M.D., clinical assistant professor of pediatrics and communicable diseases and of radiology at the U-M Medical School.

4 Jan 2011

Stryker closes acquisition of Boston Scientific Neurovascular

Stryker Corporation announced today the closing of its previously announced acquisition of the assets of the Neurovascular division of Boston Scientific, the global leader in the approximately $900 million worldwide neurovascular market, which includes products used for the minimally invasive treatment of hemorrhagic and ischemic stroke.

From Stryker 4 Jan 2011

Study: Multitude of genes are linked to adult height

As much as 90 percent of variation in adult height may be caused by genetic inheritance, but a multitude of genes are involved. Most of these have yet to be discovered.

4 Jan 2011

Aetna acquires Medicity

Aetna today announced that it has completed its acquisition of Medicity Inc., a health information exchange technology company, headquartered in Salt Lake City, Utah.

3 Jan 2011

EDAP reduces outstanding debt by $4.6 million

EDAP TMS SA, the global leader in therapeutic ultrasound, announced today that it entered into agreements with certain holders of its senior debentures and warrants to redeem part of EDAP's outstanding convertible debt and cancel some of its outstanding warrants. Pursuant to these agreements, the Company issued 1,441,743 ordinary shares in the form of American Depositary Shares in exchange for 4,558 senior debentures (equivalent to USD 4,558,000) and 986,965 warrants, reducing the current outstanding debt by USD 4.6 million to USD 10.5 million.

3 Jan 2011

Technology News and Research

Tiny light source and sensors in endoscope may detect esophageal cancer more accurately

Bioniche Life Sciences announces completion of Australian Offer and raises gross proceeds of A$12.5 million

Single cancer cell could be detected in future using new test

Star Scientific develops moist snuff tobacco product with low carcinogenic levels

Revolutions Medical reworks exclusive license with Traxyz for breast biopsy localization system

Isis commences ISIS-EIF4ERx Phase 2 studies in non-small cell lung cancer and prostate cancer

STAAR Surgical exceeds 200,000 Visian ICL global implants

Caution over frequent use of diagnostic tests for kids

New options in fertility preservation for oncology patients

ImmuVen to develop T cell receptor proteins for treating MRSA, cancer

FDA clears first automated molecular tests to diagnose and differentiate HSV infection

MGH, Veridex establish research center of excellence on circulating tumor cell technologies

New technology can help implement safe driving strategies in electric wheelchairs

Embryome Sciences announces $4M equity financing, changes name to ReCyte Therapeutics

Mercator, Pepscan enter multi-program cancer research collaboration

U-M research shows children are more frequently exposed to radiation through imaging tests

Stryker closes acquisition of Boston Scientific Neurovascular

Study: Multitude of genes are linked to adult height

Aetna acquires Medicity

EDAP reduces outstanding debt by $4.6 million

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News